ArticleClinical rheumatology2026
Novel genetic insights: Mendelian randomization implicates Felty Syndrome in atrial fibrillation risk.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesAtrial fibrillation (AF) is a common and increasing arrhythmia posing major public health challenges. While management has improved, long-term efficacy and safety remain limited. Felty Syndrome, a severe rheumatoid arthritis (RA) subtype with splenomegaly and neutropenia, offers a chance to examine the autoimmune inflammation-AF link.
methodWe employed five Mendelian randomization (MR) approaches using genome-wide association study (GWAS) data to investigate whether Felty Syndrome causes AF.
resultsWe analyzed data from the FinnGen biobank and a separate AF GWAS, selecting 17 independent SNPs as genetic instruments. We applied five MR methods, including inverse-variance weighted and MR-Egger, to estimate causal effects. Although no statistical significance was observed (e.g., weighted median beta = 0.028, P = 0.064; weighted mode beta = 0.033, P = 0.077; IVW beta = 0.021, P = 0.086; simple mode beta = 0.039, P = 0.087), a consistent trend suggested Felty Syndrome may increase AF risk. Sensitivity analyses showed robust results, with no significant heterogeneity or pleiotropy. In summary, while statistical significance was not achieved, our findings indicate a potential biological association that merits further investigation.
conclusionsThis study highlights the need to identify new risk factors to improve AF prevention and management. The lack of significance may reflect a common challenge in MR studies of rare exposures like Felty Syndrome, where weak instruments can dilute causal estimates. Future research requires larger genetic datasets and should investigate the underlying molecular mechanisms for targeted therapies. Key Points • This study first applies Mendelian randomization to explore the Felty Syndrome-atrial fibrillation link, finding a consistent positive trend across multiple methods. • By focusing on Felty Syndrome-a condition linked to high-titer rheumatoid factor-we address prior RA study heterogeneity and offer a more precise causal model. • The results highlight the need to assess AF risk specifically in seropositive rheumatoid arthritis subgroups in future research.
Indexed as
Identifiers
41807677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.